Apellis Pharmaceuticals, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
767.06 |
888.57 |
900.38 |
1,157.12 |
1,291.15 |
1,508.50 |
| Przychód Δ r/r |
0.00% |
15.84% |
1.33% |
28.51% |
11.58% |
16.83% |
| Przychód (min) |
755.85 |
805.49 |
754.24 |
1,150.52 |
1,085.03 |
1,267.68 |
| Przychód (max) |
782.59 |
1,051.99 |
1,020.18 |
1,163.72 |
1,492.83 |
1,744.13 |
| EBITDA (średnia) |
-643.99 |
-746.01 |
-755.92 |
-971.47 |
-1,083.99 |
-1,266.46 |
| EBIT (średnia) |
-644.34 |
-746.41 |
-756.34 |
-972.00 |
-1,084.58 |
-1,267.16 |
| EBIT % |
-84.00% |
-84.00% |
-84.00% |
-84.00% |
-84.00% |
-84.00% |
| Zysk netto (średni) |
-197.88 |
41.95 |
-110.13 |
127.44 |
136.35 |
257.09 |
| Zysk netto % |
-25.80% |
4.72% |
-12.23% |
11.01% |
10.56% |
17.04% |
| EPS (średnia) |
-1.64 |
0.34 |
-0.91 |
0.66 |
1.10 |
2.07 |
| Liczba analityków (Przychody) |
17 |
16 |
21 |
18 |
8 |
11 |
| Liczba analityków (EPS) |
13 |
13 |
17 |
18 |
9 |
10 |
| symbol |
APLS |
APLS |
APLS |
APLS |
APLS |
APLS |